Giuseppe A. Palumbo

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 377 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +9

Mutation and Haplotype Studies of Familial Mediterranean Fever Reveal New Ancestral Relationships and Evidence for a High Carrier Frequency with Reduced Penetrance in the Ashkenazi Jewish Population

Ivona Aksentijevich, Yelizaveta Torosyan, Jonathan Samuels et al. · The American Journal of Human Genetics · 1999 · 293 citations · Full text

Haplotype Studies, Disease Susceptibility, Genetic Disorder +13

M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro

Marzia Leidi, Elisa Gotti, Luca Bologna et al. · The Journal of Immunology · 2009 · 260 citations · Full text

Immunology, Cell Death, Pathology +16

Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.

Francesco Di Raimondo, MP Azzaro, Giuseppe A. Palumbo et al. · PubMed · 2000 · 169 citations

Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial

Esther Natalie Olíva, Caterina Alati, Valeria Santini et al. · The Lancet Haematology · 2017 · 159 citations · Full text

Eltrombopag Versus Placebo, Thrombosis, Thrombopoiesis +7